Abstract:A novel series of molecules combining imidazo[4,5‐c] pyridines, piperidines, and sulphonamide/carboxamide derivatives were synthesized and assessed for their anticancer potential against MCF‐7 and A549 cells, with cisplatin and Doxorubicin as the reference drugs. Compound 11 b exhibited remarkable inhibition, with an IC50 of 12.26 μM against A549 cells, while 11 d showed potent inhibition with an IC50 of 13.37 μM against MCF‐7 cells. Molecular docking studies against estrogen receptor alpha (ERα) indicates strong binding interactions and favourable energies compared to the co‐crystallized ligand 4‐hydroxytamoxifen. Additionally, pharmacokinetic evaluations suggest these molecules possess promising drug like qualities, making them potential therapeutic agents. Design and synthesis of a series of novel hybrid molecules that combine Imidazo[4,5‐c] pyridines with piperdines are presented in this paper. Total 17 derivatives were meticulously synthesized and characterized using 1H NMR, 13C NMR, MS and elemental analysis techniques. The in vitroanticancer activities are estimated by verifying their effectiveness against the MCF‐7 human breast adenocarcinoma and A549 lung cancer cell line, with cisplatin and doxorubicin serving as reference drugs. Several of these compounds demonstrated significant potential, displaying IC50 values within the range of 12.26–84.5 μM for A549, and 13.37–69.82 μM for MCF‐7. Notably, compound 11 bis found to be more potent than the standard drug cisplatin with an IC50 of 12.26±0.8 μM against A549 cells, while compound 11 d exhibited highest inhibition with an IC50 of 13.37±0.4 μM against MCF‐7 cells. Although its effectiveness was moderately lower when compared to doxorubicin, it still retained substantial anticancer activity. Molecular docking studies were performed to decouple the binding affinity and ligand interactions of the compounds with the estrogen receptor alpha (ERα) (PDB ID: 3ERT). The pharmacokinetic evaluation revealed favourable drug‐likeness properties for all the molecules, suggesting their potential as therapeutic agents.

Design, Synthesis, Anticancer Evaluation and Molecular Docking Study of Novel 4H‐Chromene‐7‐Azaindole‐1,2,3‐Triazole Hybrids

Design, Synthesis, and Anticancer Activity Evaluation of Hybrids of Azoles and Barbituric Acids.

Design And Synthesis Of Novel Thiazole Linked Tetrahydropyridine Analogues As Anticancer Agents

Design, Synthesis, and Screening for Anticancer and Antimicrobial Activities of New Dihydropyridine‐Anchored Pyrazole and 1,2,3‐Triazole Hybrids

Design and Click Synthesis of Novel 1- Substituted-4-(3,4-Dimethoxyphenyl)-1H-1,2,3-Triazole Hybrids for Anticancer Evaluation and Molecular Docking

Design and Synthesis of Some New Quinoxaline-Thiazole-Benzamide Hybrids: In Vitro Anticancer Activity and Their Molecular Docking Studies

Synthesis, anticancer evaluation, in‐silico ADMET and molecular docking studies for tailored pyrazolo‐benzothiazole hybrids

Design of New Benzo[h]chromene Derivatives: Antitumor Activities and Structure-Activity Relationships of the 2,3-Positions and Fused Rings at the 2,3-Positions

New 1,2,3-Triazole-Containing Hybrids as Antitumor Candidates: Design, Click Reaction Synthesis, DFT Calculations, and Molecular Docking Study

DESIGN, SYNTHESIS, MOLECULAR DOCKING STUDIES AND ANTICANCER ACTIVITY OF 5-SUSTITUTED-3-((2-(4-NITROPHENYL) THIAZOL-4-YL) IMINO)-1-(SUBSTITUTED-1-YLMETHYL) INDOLIN-2-ONE SCAFFOLDS

Synthesis of Novel 2-((3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)methylene)hydrazinyl-4-phenylthiazole: Potent EGFR Targeting Anticancer Agents

Synthesis, biological evaluation and in-silico ADMET studies of novel chalcones and dihydro pyrazoles of 2 H -Chromene as anticancer agents

1,2,3-triazole and chiral Schiff base hybrids as potential anticancer agents: DFT, molecular docking and ADME studies

Design, Synthesis, and Molecular Docking Studies of Some New Quinoxaline Derivatives as EGFR Targeting Agents

Design, Synthesis, Computational Docking and Biological Evaluation of Novel 4-Chloro-1,3-Benzoxazole Derivatives as Anticancer Agents

New 2H‐Chromene‐Based Hydrazone Derivatives as Promising Anti‐Breast Cancer Agents: Efficient Synthesis, Spectral Characterization, Molecular Docking, and ADMET Studies

Design, synthesis, and in vitro and in vivo biological evaluation of triazolopyrimidine hybrids as multitarget directed anticancer agents

Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study

Novel Coumarin‐Pyrazole‐Thiazoles Hybrids: Synthesis, Anticancer Activity, Molecular Docking and In Silico ADMET prediction Studies

Synthesis and Anticancer Evaluation of Isoxazole Ring-Containing 6-(Pyridin-4-yl)imidazo[2,1-b][1,3]thiazole Derivatives

New Imidazo[4,5‐c]pyridine‐piperidine Hybrids as Potential Anti‐cancer Agents and In‐Silico Studies